Therapeutic Solutions International Inc (TSOI)

[centsability4me]

rrao11,

from the TSOI PR dated Sept. 25th , 2018 :


One of the most advanced immunotherapies is the use of CAR-T cells, whose dose-limiting toxicity is associated with the production of inflammatory cytokines. The data filed in the patent suggest the possibility of using NanoStilbene to reduce side effects of this type of immunotherapy" said Timothy Dixon, President, and CEO of TSOI. "These data, which will be formally published in the peer-reviewed literature, we believe, strongly support the implementation of NanoStilbene in patients with advanced cancer."


From yesterday's PR on Dr. Marincola :


“Franco’s proven track record in oncology and robust research experience that spans the NIH to industry will be critical to the targeting and acceleration of our research efforts in CAR T and beyond,” said Christi Shaw, Chief Executive Officer of Kite. “As the cell therapy leader, we are thrilled to welcome Franco to our team and are confident that his exceptional skills and expertise will best position our research to discover potentially life-saving therapies for patients in need.”


6/1/20 Video of Dr. Marincola on "The future of Cancer immunotherapy:

<

.